Elevidys, which is also facing regulatory hurdles in the US, was developed by Sarepta Therapeutics but is sold by Roche outside of the US.

As first-line treatments in metastatic HER2-positive breast cancer evolve, the firm expects its HER2 targeted therapies to remain integral to growth.

Blood Cancer UK is launching early career grants following a tough pandemic-era funding climate, while US funders worry about federal cuts.

The reorganization and pipeline prioritization is expected to extend the company's operational runway into 2027 and support its long-term growth.